ALX Oncology Holdings Inc.

ALXO

Healthcare Biotechnology

EPS
+73.5%
Free cash flow
+31.7%
Total debt
−3.34%

Quarter to June 2026, against a year earlier

1.16 0.01 +0.87%
Market cap
$159.7M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
−673.3%
Net debt / EBITDA
0.3×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
9.71 7.21 2.07 2.40
Net Debt/EBITDA
7.05 6.96 1.52 2.24
Debt/Equity
0.07 0.06 0.38 0.23
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.12) (0.18) (0.35) (0.32)
Book value per Share
1.00 1.45 0.48 0.84
Free Cash Flow
(16.03) (18.70) (19.03) (17.15)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026